Replies to post #350452 on Anavex Life Sciences Corp (AVXL)

[Gator328]

Agreed, I think we are saying the same thing but you worded it better.

My point was that shareholders cannot expect $2 billion revenue forever because once other, larger scale diseases are approved for treatment it’s inevitable the cost of the drug will come down.

My fear is more that if insurance companies know that A273 is going to be submitted for other diseases, will that try to stall and avoid paying the Rett costs until the drug is priced cheaper (vs. if A273 only worked for Rett so they don’t have as much leverage in negotiating what they’ll cover?)